NCT05743842Active, not recruiting
TriNav Infusion System for the Evaluation of Fidelity Between 99mTc-MAA and Y90-Microspheres Hepatic Distribution for Dosimetry Treatment Planning
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
To learn if using the TriNav Infusion System (TriNav catheter) for the injection of the surrogate/test dose during the planning part of the radioembolization procedure and your actual treatment with the radioactive microspheres match each other better than the standard catheter.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 19 (actual)
- First submitted
- 15 Feb 2023
- Start date
- 14 Mar 2023
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05743842
What you commit to
- Study type: Interventional
- Participants enrolled: 19
- From 14 Mar 2023 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindications to angiography and selective visceral catheterization
- Evidence of potential delivery of greater than 30 Gy absorbed dose to the lungs with a single injection.
- Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow (eg, placing catheter distal to gastric vessels)
- Infiltrative tumors
- Target vessel sizes outside of TriNav device prescribed diameter range of 1.5 - 3.5 mm
Who the study is looking for
- Patients over 18 years of age, of any race or sex, who have unresectable primary or metastatic tumors of the liver, and who are able to give informed consent.
- Patients must be eligible for Y90-radioembolization treatment, have an ECOG Performance Status score of ≤ 2, with a life expectancy of ≥ 3 months, and must be non-pregnant with an acceptable contraception in premenopausal women.
- At least one lesion ≥ 3.0 cm in shortest dimension
- Negative pregnancy test in premenopausal women
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.